Humulin M3 Kwikpen (Mixture 3) (Insulin Human (Rdna))

Humulin M3 Kwikpen is indicated for the control of blood glucose in adults with diabetes when a mixed insulin regimen is appropriate.

• Basal‑bolus therapy in type 1 diabetes requiring both rapid‑acting and intermediate‑acting insulin.
• Supplemental insulin for type 2 diabetes patients who cannot achieve targets with oral agents alone.
• Transition from separate NPH and regular insulin injections to a single convenient device.
• Use in hospital or outpatient settings where subcutaneous insulin administration is required.
• Adjusted dosing for patients with variable meal patterns or physical activity levels.
• Suitable for patients who prefer a prefilled pen over vial‑and‑syringe delivery.

• Humulin M3 delivers a combination of regular insulin and NPH insulin. Regular insulin binds to insulin receptors on muscle and adipose cells, activating the receptor’s intrinsic tyrosine kinase and promoting translocation of GLUT‑4 transporters, which increases glucose uptake. The NPH component provides a prolonged basal insulin effect by slowly releasing insulin, suppressing hepatic gluconeogenesis and maintaining steady glucose control between meals and overnight.

Like all insulin preparations, Humulin M3 may cause adverse reactions at the injection site or systemic level.

Common

• Hypoglycemia, especially if meals are missed or dose is excessive.
• Injection‑site redness, swelling, or itching.
• Lipodystrophy presenting as localized thickening or thinning of subcutaneous tissue.
• Transient weight gain due to fluid retention.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms such as confusion, seizures, or loss of consciousness.
• Allergic reactions including urticaria, angioedema, or anaphylaxis.
• Persistent edema or worsening heart failure in susceptible patients.
• Unexplained hypokalemia or other electrolyte disturbances.

When prescribing Humulin M3, clinicians should evaluate patient‑specific factors and monitor for conditions that could alter insulin requirements or increase risk of complications.

• Adjust dose in renal or hepatic impairment, as insulin clearance may be reduced.
• Use caution in patients with a history of severe hypoglycemia or hypoglycemia unawareness.
• Review cardiovascular status; rapid glucose shifts can precipitate ischemic events.
• Avoid use during pregnancy unless benefits outweigh risks; it is classified as pregnancy category B.
• Monitor for signs of lipodystrophy and rotate injection sites to prevent tissue changes.
• Consider reduced dosing during periods of decreased caloric intake or increased physical activity.

Humulin M3 can interact with other medications that affect glucose metabolism, insulin sensitivity, or absorption.

Avoid

• Adding other rapid‑acting insulins without dose reduction, which may cause severe hypoglycemia.
• Combining full‑dose sulfonylureas with Humulin M3, increasing hypoglycemia risk.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Corticosteroids, which raise glucose and may require higher insulin doses.
• Thiazide diuretics, which can reduce insulin sensitivity.
• ACE inhibitors or ARBs, which may enhance insulin’s glucose‑lowering effect.
• Alcohol, especially binge drinking, which can cause unpredictable glucose changes.